European Pharmaceutical Review

AUGUST 21, 2023

For 20 of the leading biopharmaceutical companies, the second quarter (Q2) of 2023 has brought an aggregate market capitalisation growth of 2.3 Q2 2023 biopharma market capitalisation results Eli Lilly “Eli Lilly witnessed the largest market capitalisation growth of 36.1 trillion in the Q1 of 2023 to $3.56 trillion in Q2 2023.

Biopharma 78

Biopharma Marketing Sales Medicine 78

pharmaphorum

JULY 1, 2022

billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical hold while a safety signal is investigated. Those changes haven’t been enough to prevent the FDA from taking action, although outside the US the studies will continue as planned with the tighter safety monitoring.

Side effects 84

Side effects Safety Biopharma Recruitment 84

Zymewire

FEBRUARY 8, 2024

Skip to a topic Axonis' journey and purpose The impact of the economic client on emerging biopharma The place of Artificial Intelligence in drug development & discovery Working with NASA Relationships with CROs, CDMOs, and other service providers What made you want to start Axonis? sending neurons to space.

Competition 52

Competition Leads Patients Marketing 52

Clarivate

JANUARY 23, 2024

While some industry observers read this drop as a clear decline in productivity, others take a more optimistic view, attributing the decline to FDA submission calendar fluctuations and noting that 2022 numbers were not very different from the ten-year average. In fact, the number of NMEs has grown by 65% between 2013 and 2022.

Pharma 52

Pharma Sales Consulting Pharmaceutical 52

Clarivate

OCTOBER 19, 2023

the FDA offers a period of 3 years of data exclusivity for a new application of a previously approved drug. “However, drug repurposing faces multiple challenges in the regulatory area,” points out Martí Bernardo-Faura, Senior Bioinformatics Consultant at DTS Consulting Services in Clarivate. For example, in the U.S.,

Networking 59

Networking Consulting Safety Side effects 59

Pharmaceutical Technology

DECEMBER 20, 2022

The collaborative spirit arising between pharmaceutical and biotechnology companies is leading to a new rapport with regulators, as well. McCall sees the whole experience as a positive one for biopharma: “When I started in industry, this type of data sharing and collaboration was unheard of. Free Whitepaper.

Biopharma 52

Biopharma Manufacturing FDA Pharmaceutical 52

Clarivate

OCTOBER 10, 2022

Based on the TROPICS-02 trial results, Gilead has submitted a supplemental biologics license application (sBLA) to the FDA, seeking a label expansion for TRODELVY in the much larger setting of metastatic HR+/HER2-negative breast cancer. Fruquintinib will face fierce competition should it be approved in the third- and later-line setting.

Marketing 52

Marketing Safety Patients Competition 52